SCHEMBL4666409

SCHEMBL4666409

COC(=O)c1ccc(C=Cc2cc3c(cc2CBr)C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 8/20 0.53
RARG P13631 8/20 0.53
RARA P10276 7/20 0.53
CYP3A4 P08684 3/20 0.48
PTPN1 P18031 1/20 0.45
CYP26A1 O43174 3/20 0.45
VDR P11473 4/20 0.43
RXRA P19793 1/20 0.42
RXRB P28702 1/20 0.42
RXRG P48443 1/20 0.42
NPC1 O15118 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.39
S1PR4 O95977 1/20 0.39
POLB P06746 1/20 0.39
ALPG P10696 1/20 0.39
THRB P10828 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4666965 1.00 RARB (0.53) RARBRARGRARACYP3A4PTPN1
SCHEMBL10842924 0.91 RARB (0.55) RARBRARGRARACYP3A4PTPN1
SCHEMBL10842927 0.91 RARB (0.55) RARBRARGRARACYP3A4PTPN1
SCHEMBL10840768 0.89 RARB (0.51) RARBRARGRARACYP3A4PTPN1
SCHEMBL10840771 0.89 RARB (0.51) RARBRARGRARACYP3A4PTPN1
SCHEMBL6909571 0.88 RARB (0.52) RARBRARGRARACYP3A4PTPN1
SCHEMBL4709130 0.88 RARB (0.52) RARBRARGRARACYP3A4PTPN1
SCHEMBL4669351 0.88 RARB (0.52) RARBRARGRARACYP3A4PTPN1
SCHEMBL14159922 0.87 VDR (0.42) RARBRARGRARACYP3A4PTPN1
SCHEMBL10847379 0.87 RARB (0.49) RARBRARGRARACYP3A4PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1324970-B1 RETINOIDS FOR THE TREATMENT OF EMPHYSEMA HOFFMANN LA ROCHE (CH) 2008-11-05 EP disclosed
EP-1935869-A1 Retinoids for the treatment of emphysema F. HOFFMANN-LA ROCHE AG (CH) 2008-06-25 EP disclosed
US-6777418-B2 FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS SYNTEX (U.S.A.) LLC 2004-08-17 US disclosed
EP-1324970-A2 RETINOIDS FOR THE TREATMENT OF EMPHYSEMA F. HOFFMANN-LA ROCHE AG (CH) 2003-07-09 EP disclosed
US-20020082265-A1 For treating or preventing emphysema, cancer and dermatological disorders SYNTEX (U.S.A.) LLC 2002-06-27 US disclosed
WO-2002028810-A2 RETINOIDS FOR THE TREATMENT OF EMPHYSEMA F. HOFFMANN-LA ROCHE AG (CH) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082265-A1 For treating or preventing emphysema, cancer and dermatological disorders RXRA, RXRG, RXRB RARB 6/4885RARG 4/4885RARA 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.